The role of FCRN antagonists in transforming the myasthenia gravis treatment paradigm

Key Points

• FCRN antagonists improve treatment outcomes in myasthenia gravis, indicating a significant advancement in management.
• Clinical trials have shown that these agents can reduce symptoms and improve muscle strength in affected individuals.
• This analysis reviews the use of FCRN antagonists in treating autoimmune disorders, focusing on their efficacy and safety profiles.
• Findings suggest this new treatment paradigm may lead to better control of symptoms and quality of life for patients.